What is the recommended management of hepatorenal syndrome?

Management of Hepatorenal Syndrome

The treatment of choice for hepatorenal syndrome is vasoconstrictor therapy (terlipressin as first-line, or norepinephrine if unavailable) combined with intravenous albumin, with all patients requiring urgent evaluation for liver transplantation as the only definitive cure. 1

Diagnostic Confirmation

Before initiating treatment, confirm the diagnosis by excluding other causes of acute kidney injury 1:

• Serum creatinine ≥1.5 mg/dL (or meeting modified KDIGO criteria: increase ≥26.5 μmol/L within 48 hours or ≥50% from baseline within 7 days) 1
• Exclude volume depletion: No sustained improvement after diuretic withdrawal and plasma volume expansion with 1.5 L isotonic saline (or albumin 1 g/kg/day up to 100 g/day to achieve central venous pressure of 3 cm H₂O) 1
• Exclude other causes: No shock, nephrotoxic drugs, parenchymal kidney disease (proteinuria <500 mg/day, no microhematuria, normal renal ultrasound) 1

First-Line Pharmacologic Treatment

Terlipressin + Albumin (Preferred)

Terlipressin is the most effective vasoconstrictor with response rates of 64-76% for HRS reversal 1:

• Initial dose: 0.5-1 mg IV every 4-6 hours (bolus) or 2-12 mg/24h continuous infusion 1
• Dose escalation: Increase to maximum 2 mg every 4-6 hours if serum creatinine does not decrease by ≥25% at day 3 1
• Albumin: 1 g/kg on day 1 (up to 100 g), then 40 g/day IV 1
• Duration: Continue until serum creatinine <1.5 mg/dL or for maximum 14 days 1
• Continuous infusion advantage: Equally effective as boluses but with lower daily doses and reduced risk of ischemic complications 1

Response criteria: Creatinine decrease to <1.5 mg/dL or return to within 0.3 mg/dL of baseline 1

Discontinuation: If creatinine remains at or above pretreatment level after 4 days at maximum tolerated doses, therapy may be stopped 1

Alternative Vasoconstrictors

Norepinephrine + Albumin (if terlipressin unavailable or patient has central venous access) 1:

• Requires ICU setting with central venous catheter 1
• Reported 83% success rate in reversing type I HRS 1
• Meta-analyses show no significant difference in HRS reversal compared to terlipressin 1

Octreotide + Midodrine + Albumin (third-line option, lower efficacy) 1:

• Octreotide: 100-200 μg subcutaneously every 8 hours (target 200 μg TID) 1
• Midodrine: Titrate up to 12.5 mg orally every 8 hours to achieve mean arterial pressure increase of 15 mm Hg 1
• Albumin: 10-20 g IV daily 1
• Advantage: Can be administered outside ICU or even at home 1
• Limitation: Efficacy is low; midodrine appears required (octreotide alone is not beneficial) 1

Monitoring and Safety

Close monitoring required for vasoconstrictor complications 1:

• Ischemic events: Cardiovascular, intestinal, or distal necrosis (occur in ~12% of patients) 1
• Pulmonary edema: From albumin and fluid shifts 1
• Contraindications: Exclude patients with severe cardiovascular or ischemic conditions 1

Parameters to monitor 1:

• Urine output, fluid balance, arterial pressure
• Central venous pressure (ideally) to prevent volume overload 1
• Serum creatinine, bilirubin, sodium
• Mean arterial pressure increase >5 mm Hg at day 3 predicts response 1

Liver Transplantation

All patients with HRS-AKI require urgent liver transplant evaluation given high short-term mortality even in treatment responders 1:

• Definitive cure: Liver transplantation is the only curative treatment, known effective for 30 years 1
• Expedited referral: Patients with type I HRS should have accelerated transplant evaluation 1
• MELD score consideration: Successful HRS treatment reduces creatinine and MELD score, potentially disadvantaging patients; some countries maintain pretreatment MELD or assign extra points 1
• Simultaneous liver-kidney transplant: May be necessary for patients not expected to recover kidney function post-transplant 1

Renal Replacement Therapy

RRT indications are limited and context-dependent 1:

• Use in transplant candidates: For worsening renal function, electrolyte disturbances, or volume overload unresponsive to vasoconstrictors 1
• Non-transplant candidates: Prognosis with RRT is very poor; initiate only with clear endpoint (e.g., reversible precipitating event like sepsis) 1
• Technique: Continuous venovenous hemofiltration causes less hypotension than hemodialysis but requires continuous dialysis nurse involvement 1
• Survival without transplant: Dismal (historical series: 0/25 survivors; recent data: 8/30 survived 30 days) 1

Recurrence Management

Recurrence after treatment discontinuation occurs but is uncommon 1:

• Retreatment: Generally effective with same vasoconstrictor regimen 1
• Recurrent HRS: Response rates significantly lower (20% vs. 64-76% for initial episode) 1

Multidisciplinary Decision-Making

Complex management requires team approach 1:

• Decisions about vasoconstrictor therapy and RRT should involve hepatology, nephrology, critical care, and transplant surgery specialists 1
• This is particularly important given the complexity of HRS-AKI diagnosis and poor prognosis 1

Common Pitfalls

• Avoid terlipressin in ACLF grade 3 or serum creatinine ≥5 mg/dL: Elevated risk of respiratory failure with limited benefit 2
• Do not delay transplant evaluation: Even responders to vasoconstrictors have high early mortality without transplantation 1, 3
• Recognize serum creatinine limitations: Muscle wasting, ascites, and elevated bilirubin affect creatinine accuracy in cirrhosis 1
• Distinguish from ATN when possible: Vasoconstrictors not justified for ATN; urinary NGAL (cutoff 220-365 μg/g) may help differentiate 1